Abstract-Regulatory T cells (T reg cells) play important roles in hypertension and organ damages. is a critical regulator for T reg cell generation. However, the role of miR-31 in hypertension has not been elucidated. We aim to study the functionality of miR-31 and the detailed mechanism in Ang II (Angiotensin II)-induced hypertensive mouse model. We found: In vitro, miR-31 expression was higher in T helper 17 cells and lower in T reg cells than that of naïve T cells. The genetic deficiency of miR-31 promoted T reg cell differentiation, whereas no impact on T helper 17 cells differentiation. Ang II-induced hypertension resulted in increased expression of miR-31 in the aorta, splenic CD4 + T cells, and kidney leukocytes. MiR-31 deficiency strikingly decreased systolic blood pressure and diastolic blood pressure and attenuated renal and vascular damage. MiR-31 deletion altered the accumulation of T reg cells and macrophages and expression of inflammatory cytokines in kidneys in Ang II-induced hypertensive mice. Ang II treatment reduced the levels of anti-inflammatory cytokines and increased proinflammatory cytokines in plasma that were blunted by the miR-31 deletion. Ppp6C (protein phosphatase 6c; a direct target of miR-31) specific deletion in T reg cells led to marked impairment of T reg cell induction, increased Ang II-induced blood pressure elevation, and organ damage in mice. In conclusion, we provided novel evidence of miR-31 as an emerging key posttranscriptional regulator of hypertensionassociated immunosuppression through targeting ppp6C which is a critical regulator in the differentiation of T reg cells. This study offers new perspectives on miRNA-based therapeutic approaches. (Hypertension. 2019;73:e14-e24.
merging evidence has demonstrated that both innate and adaptive immune responses play critical roles in the development of hypertension and subsequent target organ damage. 1, 2 The importance of specific subsets of T cells (T helper 17, Th1, and regulatory T cells [T reg ] cells) and the cell-derived cytokines in the pathogenesis of hypertension has been well recognized. [3] [4] [5] [6] [7] T reg cells, as of special interest, is an immunosuppressive T-cell lineage, whose immune-suppressive effects are exerted by acting on effector T cells and other immune cells, such as macrophages, and mediated by cell-cell contact mechanisms or via the release of anti-inflammatory cytokines like IL (interleukin)-10. [8] [9] [10] [11] Both adoptive transfers and modulation to increase T reg cell numbers protect blood pressure (BP) elevation and target organ damage induced by Ang II (angiotensin II). 5, 7, 12, 13 In the meantime, Ang II infusion results in decreased numbers of T reg cells in the kidney of hypertensive mice. 12 Thus, deeper understanding of molecular mechanisms underlying T reg cell generation may allow profound insights into physiological and pathological immune responses for the intervention against hypertension and target organ damage. MicroRNAs (miR) have been implicated in inflammation and are known to regulate gene expression by translational repression and mRNA destabilization. Several studies have observed specific miR signatures for specialized T-cell subsets, and these miR are dynamically modulated during T-cell differentiation.
14 Recently, miR-31, a pleiotropically acting tumor suppressor miR, 15 has been identified as a molecular checkpoint of T-cell differentiation and function. Forkhead box P 3 encoding a master regulator of the differentiation and activation of T reg cells binds to and represses the miR-31 promoter in the induced T reg cells, which is directly suppressed by miR-31. 16, 17 Recurrent data have demonstrated that miR-31 negatively regulates peripheral T reg cell generation by targeting G-protein-coupled receptor family C group 5 member A and increased experimental autoimmune encephalomyelitis severity. 17 Therefore, modulation of T reg cell generation by inhibiting miR-31 may be a feasible strategy for the intervention of hypertension and organ damage.
Numerous studies have demonstrated that miR-31 plays a crucial role in a plethora of immune system disorder diseases by regulating genes involved in cell differentiation, proliferation, and migration. 18 Decreasing MiR-31 attenuated the development of sepsis by increasing Th2 cells and increased IL-4, 19 another evidence suggesting reduced circulating Th2 frequency and decreased IL-4 in patients with hypertension. 20 Repression of miR-31 by B cell lymphoma 6 protein is restricted to control human follicular helper T-cell differentiation, but not mouse. 21 MiR-31 promotes CD8 + T-cell exhaustion during the chronic stage of infection. 22 Downregulation of miR-31 in the T reg cells is required for the maintenance of FoxP3 expression to regulate the differentiation and function of T reg cells and results in a significant decrease in the severity of experimental autoimmune encephalomyelitis. 16 The genetic deficiency of miR-31 inhibits keratinocyte hyperproliferation by targeting ppp6C, decreases acanthosis, and reduces the disease severity in psoriasis mouse models. 23 Moreover, miR-31 has been shown to be involved in the vascular injury; its expression was significantly increased in proliferative vascular smooth muscle cells and vascular walls with neointimal growth in the rat carotid artery balloon injury model. 24 However, the physiological significance and the in vivo function of endogenous miR-31 remain unexplored in hypertensive mouse models, and no evidence implicates the effect of miR-31 in the regulation of T reg cell generation in Ang II-induced BP elevation.
In view of the known about miR-31 regulation of Tregs and other cells, and the role of these cells in reducing BP, particularly, considering the inhibitory functions of miR-31 on Tregs, whose immune-suppressive effects may help protect BP elevation and target organ damage, we state a hypothesis that miR-31 could contribute to the Ang II-induced hypertension. In this study, we used miR-31 −/− , miR-31 flox/flox CD4-Cre (miR-31fl/ fl*CD4-Cre) and ppp6C flox/flox FoxP3 GFP -Cre (ppp6C-cKO) mice and intended to determine the possible role of miR-31 in BP regulation and depict the mechanisms. We showed that miR-31 expression was downregulated by TGF (transforming growth factor)-β1-induced FoxP3 and the deletion of miR-31 led to enhanced induction of T reg cells in vitro differentiation conditions. MiR-31 expression was increased in the aorta and kidney in Ang II-induced hypertensive mice. Furthermore, we investigated the effect of miR-31 in Ang II-induced BP elevation and target organ damage and explored the mechanism that might be via regulating T reg cell differentiation and function through targeting ppp6C that is essentially required for T reg cell generation.
Materials and Methods
The authors declare that all supporting data are available within the article (and in the online-only Data Supplement).
Statistical Analysis
The data were analyzed with GraphPad Prism 5 or 8 and were presented as the mean±SEM. In total, 3 different test methods were applied accordingly. Student t test was used when 2 conditions were compared, and ANOVA with Bonferroni test was used for multiple comparisons (1-way or 2-way). All data conducted for different tests had passed the normality test. Probability values of <0.05 were considered statistically significant, *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; ns, not significant. Error bars depicted SEM.
Detailed description of the experimental procedures is available in the online-only Data Supplement.
Results

MiR-31 Negatively Regulates T reg Cell Differentiation and Is Increased in Ang II-Induced Hypertensive Mice
Consistent with previous studies, 17 we here demonstrated that miR-31 exhibited a distinct expression pattern in T helper 17 and T reg cells polarized from naïve CD4 + T cells compared with that of purified naive CD4 + T cells ( Figure 1A and 1B). These T-cell subsets are critical in the pathology of hypertension. 4, 5, 12 We further found that the lack of miR-31 did not lead to significant change of T helper 17 cell differentiation ( Figure 1C ) yet markedly induced T reg cell differentiation in vitro ( Figure 1D ). Consistently, we also found that the lack of miR-31 markedly enhanced T reg cell differentiation in a TGF-β1 dose-dependent manner from naive CD4 + T cells of miR-31 −/− mice compared with C57 (wild type [WT]) controls ( Figure 1E and 1F) . Thus, these data suggested that miR-31 negatively regulated the generation of T reg cells which are vital for preventing hypertension. 12 Next, we induced hypertension in WT mice by infusion with Ang II (WT-A) and measured systolic BP (SBP; Figure 2A ) using tail-cuff. MiR-31 expression was assessed in the aorta, splenic CD4 + T cells, or kidney leukocytes (the purify of CD45 + leukocytes was nearly over 98% showed in Figure S2B ); we found that the expression of miR-31 was significantly increased in the aorta, splenic CD4 + T cells, and kidney leukocytes from WT-A group compared with WT-C control group ( Figure 2B ). These data strongly support that miR-31 was increased in Ang II-induced hypertensive mice. The increased expression of miR-31 in the damaged organ prompted us to assess its in vivo functionality in the development and progression of hypertension in Ang II-induced hypertensive mouse model.
MiR-31 Deficiency Ameliorates Ang II-Induced Hypertension and Target Organs Damage in Mice
To determine the role of miR-31 in BP regulation, we induced the Ang II-infused hypertensive model in WT and miR-31 −/− mice and monitored BP using noninvasive tail cuff. Tail-cuff BP measurements revealed that miR-31 −/− mice manifested drastically blunted SBP elevation compared with WT mice, and miR-31 −/− mice with SBP displayed averagely 26 mm Hg lower SBP after 14 days of Ang II infusion when compared with controls ( Figure 2C ). Renal and vascular damages are caused during Ang II-induced hypertension. 25 We, therefore, studied the impact of miR-31 deficiency on Ang II-induced renal and vascular damages in the miR-31 −/− mice. The histological analysis of kidney sections illustrated that miR-31 deficiency restrained Ang II-induced glomerular collagen deposition by Masson Trichrome staining and glomerular hypertrophy by Hematoxylin and eosin staining ( Figure 2D ). We further examined the aorta structural changes, and we demonstrated that 2 weeks of Ang II infusion caused hypertrophy of aortas (intima and media), which was mitigated in miR-31 −/− mice; Masson Trichrome staining showed that Ang II-induced fibrosis of aorta was significantly reduced in miR-31 −/− mice compared with WT controls ( Figure 2E ). These data demonstrated that the deficiency of miR-31 was able to ameliorate Ang II-induced target organs damage.
miR-31 Deficiency Attenuates Ang II-Induced Target Organ Inflammation
Inflammation including inflammatory cells and genes plays important roles in mediating target organ dysfunction, 3 and that is a major contributing factor to BP elevation in both clinical and experimental settings.
3,25 Accumulation of T cells and macrophages into kidneys has been observed in hypertension, and these inflammatory cells mediated the renal damage partly. 3 Interestingly, miR-31 deficiency mitigates Ang II-induced accumulation of CD45 + F4/80 + macrophages in kidney ( Figure 3B ). We further showed that Ang II decreased the percentage of CD4 +
FoxP3
+ T reg cells in the kidney, and this downregulation was notably diminished in miR-31 −/− mice compared with WT mice ( Figure 3A) . Gating strategy for flow cytometric analysis was described ( Figure S2A ). These data suggest that miR-31 deficiency mitigates Ang II-induced decrease of T reg cells and increased numbers of macrophages in kidney. Next, we investigated the induction of inflammatory genes in kidney from those 4 groups. Compared Ang II-infused miR-31 −/− mice to WT mice, we found that Ang II-induced expression of many inflammatory genes in the kidneys ( Figure 3C ), including VCAM-1 (vascular cell adhesion molecule 1), MCP-1 (monocyte chemotactic protein 1), and IL-6, which expression was reduced. And the critical markers for renal injury including NGAL (neutrophil gelatinaseassociated lipocalin) and OPN (osteopontin) that expression was attenuated too. Anti-inflammatory IL-10 expression was increased. Fibrotic mediators and markers for the kidney, including collagen I and TGF-β, both expression was decreased. Additionally, we investigated the structure of renal cortical tissue from those 4 groups mice. Glomerular foot process (GFP) fusion was observed in Ang II-infused WT mice, but not in miR-31 −/− mice ( Figure 3D ), and the thickness of glomerular basement membrane (GBM) was increased when comparing Ang II-infused WT mice with miR-31 −/− mice ( Figure 3E ). The karyopyknosis of tubular epithelial cells was found in Ang II-infused WT mice, but not in miR-31 −/− mice, and mitochondria were obviously swollen and dilated, and some mitochondrial membrane was disrupted and collapsed seriously when comparing Ang II-infused WT mice with miR-31 −/− mice ( Figure 3F ). Finally, we found decreased protein levels of proinflammatory TNF (tumor necrosis factor)-α, IL-6, Regulated upon Activation Normal T-Expressed and Secreted, and increased anti-inflammatory IL-10 in miR-31−/− mice compared with WT mice in plasma after Ang II infusion ( Figure S4 ). Taken together, our data suggest that miR-31 deficiency attenuated Ang II-induced organ inflammation and glomerular injury and balanced the levels of anti-inflammatory cytokines and proinflammatory cytokines in the plasma.
MiR-31 Conditional Deletion in CD4 + T Cells Attenuates Ang II Induced-Hypertension and the Decreased T reg Cell
We used mice with the miR-31 conditional knockout in CD4 + T cells (miR-31-cKO, Genotype identification of the mice was showed in Figure S1A ) and then surgically implanted a BP catheter with a radio transmitting system followed by Ang II infusion. We then monitored BP of mice by radio telemetry and found that miR-31-cKO mice revealed a markedly lower BP, with averagely SBP 23 mm Hg lower and diastolic BP 12 mm Hg lower compared with miR-31 flox/flox mice in the whole process after Ang II infusion ( Figure 4A and 4B) . Telemetry BPs measured at day 13 after Ang II infusion in miR-31-cKO mice remained blunted compared with miR-31 flox/flox controls during 24 hours ( Figure 4C and 4D) . The continuous SBP values of the 24-hour recorded period at day 13 after Ang II infusion were presented with dots ( Figure S3 
Ppp6C Is Functionally Important for the Biological Effects of miR-31 in Hypertension
A previous study confirmed that ppp6C was one of the key targets of miR-31 and contributed to basal keratinocyte proliferation and epidermal hyperplasia in psoriasis. 23 Here, we found that ppp6C expression was significantly decreased in the kidneys of Ang II-infused hypertensive mice (WT-A group) compared with either normotensive control mice (WT-C group) or Ang II-treated and untreated miR-31 −/− mice; however, no significant difference of ppp6C expression was observed between the Ang II-treated and untreated miR-31 −/− mice, indicating that ppp6C is a potential miR-31 target in hypertension ( Figure S5A through S5C) .
Prompted by these results, we next aimed to identify whether the miR-31 target gene ppp6C could be accountable for the observed effects of miR-31 deficiency in Ang IIinfused hypertensive mice. First, we checked the direct role of ppp6C in BP regulation by using ppp6C-cKO and Foxp3 GFP -Cre mice (Genotype identification of the mice was shown in Figure S1B ) with 750 or 550 ng/kg per minute Ang II or 0.9% NaCl infusion and found that ppp6C-cKO mice manifested drastically increased SBP elevation compared with FoxP3 GFP -Cre mice, ppp6C-cKO mice with averagely 16 mm Hg or 14 mm Hg higher SBP after 14 days of above 2 dose of Ang II infusion, respectively, SBP were increased in both ppp6C-cKO and FoxP3 GFP -Cre mice in a dose-dependent manner during Ang II infusion, and there was no more pronounced difference significant comparing 750 to 550 ng/kg per minute after Ang II infusion between ppp6C-cKO and FoxP3 GFP -Cre mice ( Figure 5A and 5B). The histological analysis illustrated that ppp6C-cKO mice accelerated Ang II-induced hypertrophy of glomerular after 750 or 550 ng/kg per minute Ang II infusion (Figure S7A and S7B; Figure 5D ); similar results were obtained in mice infused with above 2 doses of Ang II, suggesting the optimum response was reached at 550 ng/kg per minute Ang II infusion. Then, we found glomerular collagen deposition was accelerated ( Figure 5C ), and the level of 24-h urinary mALB (microalbumin) was increased after 550 ng/ kg per minute Ang II infusion in ppp6C-cKO compared with FoxP3 GFP -Cre mice ( Figure 5E ). These data suggest that the deficiency of ppp6C in FoxP3 + T reg cells was able to facilitate Ang II-induced BP elevation and renal damage.
Then, in vitro, we found that the lack of ppp6C markedly inhibited T reg cell differentiation from naive CD4 + T cells of ppp6C-cKO mice compared with Foxp3 GFP -Cre controls ( Figure 6A and 6B). Ang II decreased the percentage of CD4 + FoxP3 + T reg cells in the kidney, and this downregulation was notably increased in ppp6C-cKO mice compared with FoxP3 GFP -Cre mice (Figure 6Cand 6D) . Collectively, these data suggest that miR-31 targets ppp6C and negatively regulates T reg cell generation, and the miR-31-ppp6C-Tregs axis strongly contributes to immunosuppression in Ang II-induced hypertension.
Discussion
The role and molecular mechanism of miR-31 in the regulation of BP remain unclear, although it is well documented that Ang II-induced hypertension results in a decreased number and dysfunction of T reg cells, 7 which is negatively regulated by Mito; F) . These images are taken by using magnification ×15000 (Scale bars 1 µm) . WT indicates wild-type; FSC-A, forward scatter-area. miR-31 17 . In the present study, we revealed that the genetic deficiency of miR-31 significantly induced T reg cell differentiation and effectively ameliorated Ang II-induced hypertension by targeting ppp6C ( Figure S8 ). Mechanistically, downregulation of miR-31 increased the proportion of FoxP3 + T reg cells, which attenuated Ang II-induced inflammatory factor expression, target organ damage, and eventually BP elevation.
Despite numerous efforts investigating the precise cause of BP elevation, the underlying mechanisms are not completely elucidated. Recently, emerging evidence reveals that miR-31 plays an important role in the progression of cancer, autoimmune disorders, such as psoriasis and experimental autoimmune encephalomyelitis, 17, 23 and cardiovascular disease 26 by targeting specific genes, which modulate cell proliferation, cell differentiation, apoptosis, and cell motility. 18 MiR-31 has been shown to sensitize breast cancer cells to invasion by targeting GNA13 (G protein alpha-13) 27 to modulate keratinocyte differentiation with a targeting effect on factor-inhibiting HIF1 (hypoxia-inducible factor 1), 28 to promote epidermal hyperplasia by repressing ppp6C in psoriatic keratinocytes and to contribute to psoriatic inflammation by regulating inflammatory cytokine induction and leucocyte migration to skin in psoriasis, 23, 29 and to negatively regulate peripherally derived T reg cell generation by repressing target gene Gprc5 and promote the development of experimental autoimmune encephalomyelitis. 17 Inhibition of miR-31 protected the heart and reduced myocardial infarct size as shown by treatment of postinjury cardiac myocytes with miR-31 inhibitor during cardiac ischemia/reperfusion injury. 26 miR-31 negatively regulates lymphatic vascular lineage-specific differentiation and vascular development by directly suppressing PROX1 (Prospero homeobox 1) encoding lymphatic transcription factor 28 to enhance vascular smooth muscle cells proliferation via inhibiting target gene, the LAST2 (large tumor suppressor homologue 2), 24 to counteract immunosuppression in human sepsis and hypertensive patients by inhibiting Th2 cytokines, 19, 20 and to stabilize the helper function of human follicular helper T cells via downregulating expression of CD40L and SAP (SLAM-associated protein). 21 To our knowledge, no prior study has addressed the possible direct intrinsic role of miR-31 in the pathogenesis of hypertension. Here, we demonstrate that miR-31 expression is significantly increased in aorta, splenic CD4 + T cells, and kidney leukocytes from the Ang II-infused hypertensive mice, the deficiency of miR-31 flox/flox and miR-31-cKO mice at day 13 after Ang II infusion (n=4). Twoway ANOVA was used, and data passed the normality test. *P<0.05, **P<0.01, ***P<0.001. ns indicates not significant.
leads to prevent Ang II-induced BP elevation, organ damage, and the reduced proportion of FoxP3 + T reg cells in the kidney. MiR-31 has been shown to be downregulated in human or mouse T reg cells. 16, 17 FoxP3 is reported to be directly suppressed by miR-31, which encodes a master regulator of the differentiation and activity of T reg cells. 16 It is well established that Ang II-induced hypertension results in a dramatic decrease of FoxP3 + T reg cells in the damaged organs. 18 Both deficiency of T reg cells and deletion of anti-inflammatory cytokine (such as IL-10) released from T reg cells aggravate hypertensive vascular injury. 5, 13 Yet, the in vivo function of miR-31-regulated T reg cells and the underlying mechanism by which it modulates T reg cell generation and activation in hypertension has not been explored. Here, we identified that miR-31 was preferentially decreased in T reg cells, and miR-31 deficiency enhanced naive CD4 + T-cell differentiation into T reg cells in vitro, which is consistent with a recent report. 17 The deletion of miR-31 resulted in an increased percentage of T reg cells in the kidney and enhanced immunosuppressive roles of T reg cells during hypertension, reduced target organ damage, and lower BP in the Ang II-induced hypertensive mouse model. These data noted above demonstrate that modulation of miR-31 expression in T reg cells may provide a basis for studies leading to potential therapies for hypertension.
Although miR-31 was identified to directly target ppp6C to facilitate keratinocyte hyperproliferation and promote psoriasiform skin disease in the imiquimod-induced mouse model, 23 the in vivo function of ppp6C in regulating T reg cell differentiation in hypertension has not been studied. Here, we present the following evidence to support that ppp6C is one of the primary targets for miR-31 in T reg cell differentiation. First, ppp6C expression is significantly decreased in diseased kidneys of WT control mice but not in the miR-31-deficient mice treated with Ang II. Second, genetic deficiency of ppp6C in FoxP3 + Treg cells results in facilitating Ang II-induced BP elevation and renal damage. Third, in vitro, the lack of ppp6C markedly inhibited T reg cell differentiation of naïve CD4 + T cells from ppp6C-cKO mice compared with FoxP3 GFP -Cre control mice. Fourth, in vivo Ang II decreased the percentage of CD4 + FoxP3 + T reg cells in kidney, and this downregulation was notably increased in ppp6C deletion of ppp6C-cKO mice compared with controls. We here demonstrated that the deletion of ppp6C (the direct target of miR-31) in FoxP3 + T reg cells led to a marked reduction of numbers of T reg cells and more severe phenotype in Ang II-induced hypertension. The observed effects in ppp6C-cKO T reg cells and mice might support that the miR-31/ppp6C/T regs axis played a critical role in the BP alterations in mice. Our data strongly suggest that miR-31 negatively regulating T reg cell generation contributes to immunosuppression in Ang II-induced hypertension by targeting ppp6C. Modulation of ppp6C expression in T reg cells may provide a basis for studies that lead to potential therapies for hypertension.
We have demonstrated that proinflammatory cytokines, including IL-6 and IL-17, are capable of triggering miR-31 transcription via NF-κB (nuclear factor κB) signaling in keratinocytes. 23 Thus, the enhanced expression of miR-31 in activated CD4 + T cells, likely a consequence of the production of excess proinflammatory cytokines, may therefore contribute to decreased numbers of T reg cells in the Ang II-induced hypertensive mouse model. In our study, Ang II treatment induces proinflammatory cytokines that act as upstream stimuli of miR-31 which inhibits the generation of T reg cells in Ang II-induced hypertensive mice.
In summary, our results demonstrate that deletion of miR-31 increases T reg cell generation through directly targeting ppp6C, promotes its immunosuppressive function, and attenuates BP elevation phenotype in mouse models of hypertension. To our knowledge, this study for the first time presents in vivo genetic evidence that miR-31 and its target ppp6C are critical intrinsic factors for controlling physiological and pathological immune responses regulated during hypertension. Our further study aimed at the strategies how to regulate the expression of miR-31 and ppp6C, or the role of miR-31 regulating the other cells such as Th2 and follicular helper T cells, which may be a promising therapeutic approach in hypertension.
Perspectives
This study displays that miR-31 regulated in vitro-induced regulatory T cell generation by targeting ppp6C and effectively controlled Ang II-induced hypertension and target organs damage, which is a novel target of hypertension treatment.
